Q-omics provides the consensus-scored SAMD12 profile across patient tissues and cancer cell-line models. SAMD12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SAMD12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SAMD12 RNA expression shows 27,395 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where SAMD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD12 survival associations across molecular data types. SAMD12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD12 RNA expression–survival associations across cancer types. High SAMD12 expression shows unfavorable associations in UCEC, but favorable associations in SKCM, ACC, KIRC, HNSC and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SAMD12 RNA expression.
This table summarizes SAMD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SAMD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD12 shows lower tumor expression in KIRC and LIHC and higher tumor expression in KIRP, STAD, BRCA and CHOL. The KIRC box plot shows higher SAMD12 RNA expression in normal versus tumor tissue (log2 FC = −1.785, t-test p < 0.001).
This table shows molecular features associated with SAMD12 in patient tissues and cancer cell lines. In patient samples, SAMD12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
